Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
E. R. Squibb & Sons, Inc. Patents
Assignee:
E. R. Squibb & Sons, Inc.
Address:
Princeton, NJ
No. of patents:
1537
Patents:












Patent Number Title Of Patent Date Issued
RE33072 Benzothiazepine derivatives September 26, 1989
Vasodilating activity is exhibited by compounds having the formula ##STR1## n is 2 or 3; X is oxygen or sulfur,R.sub.1 and R.sub.2 are each independently hydrogen alkyl, cycloalkyl, or allyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are pyrrol
RE30990 Benzimidazole derivatives, compositions thereof and method of use as anthelmintics July 6, 1982
Benzimidazolederivatives are provided having the structure ##STR1## wherein R.sup.1 is lower alkyl, phenyl-lower alkyl, halo-lower alkyl, mono-lower alkylaminoalkyl, di-lower alkylaminoalkyl, and alkyl pyridinium halide, R.sup.2 and R.sup.3 may be the same or different and are hydrog
H734 Method for inhibiting onset of or treating migraine headaches employing an ACE inhibitor February 6, 1990
A method is provided for inhibiting onset of or treating migraine headache by administering an ACE inhibitor, such as captopril, alone or in combination with a calcium channel blocker such as diltiazem or nifedipine, over a prolonged period of treatment.
H725 Ureido amino and imino acids, compositions and methods for use January 2, 1990
Compounds of the formula ##STR1## wherein X is various amino or imino acids and esters are disclosed. These compounds are useful due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enk
H672 Stable antifungal capsule formulation September 5, 1989
In accordance with the present invention an antifungal capsule formulation providing enhanced stability for antifungal agents subject to oxidative degradation, e.g. nystatin, is disclosed. The new formulation comprises an antifungal agent, in an amount of from about 0.1 to about 50 perce
H642 Substituted urido amino and imino acids and esters June 6, 1989
Compounds of the formula ##STR1## wherein X is various imino or amino acids or esters are disclosed. These compounds possess angiotensin converting enzyme inhibition activity and depending upon the definition of X also possess enkephalinase inhibition activity.
H1286 Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an February 1, 1994
A method is provided for treating peripheral atherosclerotic disease (arteriosclerosis obliterans) and/or intermittent claudication employing a cholesterol lowering drug such as an HMG CoA reductase inhibitor alone and/or an inhibitor of the enzyme squalene synthetase and optionally a
H1139 Combination of a calcium channel blocker and thromboxane A.sub.2 receptor antagonist or syntheta February 2, 1993
A method is provided for treating ischemia in a mammalian species by administering a combination of a calcium channel blocker such as diltiazem, SQ 31,765 or SQ 32,324 and a thromoboxane A.sub.2 receptor antagonist such as SQ 30,741 or a thromboxane synthetase inhibitor such as dazox
D303575 Wound drainage bag September 19, 1989
D303574 Wound drainage bag September 19, 1989
D297575 Pharmaceutical tablet September 6, 1988
6630502 Method for preventing, stabilizing or causing regression of atherosclerosis employing a combinat October 7, 2003
A method is provided for slowing the progression of atherosclerosis in hypertensive or normotensive patients and reducing or eliminating atherosclerotic lesions in such patients by administering a combination of a cholesterol lowering drug such as pravastatin, and an ACE inhibitor, e
6602232 Ostomy system with repositionable pouch August 5, 2003
The ostomy system with mounting wafer and repositionable pouch includes a resealable tape provided on one of the system members and a releasable film provided on the other system member. In a preferred embodiment of the invention the resealable tape is located on a faceplate of the pouch
6551794 Stable biotinylated biomolecule composition April 22, 2003
Stable compositions containing biotinylated molecules, such as enzymes, are provided. The compositions include a biotinylated biomolecule, a biomolecule protectant, a buffer, a bulking agent selected from one or more water soluble, nonionic polymers and preferably a terminal steriliz
6416971 Soluble single chain T cell receptors July 9, 2002
Soluble, single chain T cell receptors, nucleic acid sequences, particularly DNA sequences, encoding the soluble, single chain T cell receptor, expression vectors containing the DNA sequences, and host cells containing the expression vectors.
6387082 Ostomy appliance and wound drainage device and method of using the same May 14, 2002
An ostomy appliance or wound drainage device having a receptacle side component including a receptacle for receiving and storing waste solids and fluids and a bodyside component for adhering to the patient's skin around the stoma in which the two components are releasably sealed toge
6284285 Tissue repair promoting composition September 4, 2001
A method for isolating tissue repair promoting substances from human or animal blood, which method comprises collecting the human or animal blood from a single human or animal individual in a first container of a container system comprising at least first and second interconnected co
6187752 Method for treating schizophrenia employing an ace inhibitor February 13, 2001
A method is provided for treating schizophrenia in a mammalian species by administering an ACE inhibitor, such as captopril, alone or with a neuroleptic such as cholecystokinin, fluphenazine or haloperidol.
6117885 Biphenyl-substituted quinoline derivatives September 12, 2000
Compounds of the formula ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, A, B, D and E are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
6087349 Method for blocking neoplastic transformation of cells induced by ras oncogenes July 11, 2000
A method is provided by blocking or preventing the prenylation of CAAX box containing proteins including ras oncogene products thereby preventing and/or treating ras-related tumors which includes the step of administering a therapeutically effective amount of a protein-prenyl transfe
6066773 Thin film dressing with absorbent border May 23, 2000
A thin film device for medical applications such as a wound dressing including an occlusive layer having an edge portion about at least a portion of the thin film device and a non-continuous, hydrocolloid-containing polymeric support layer overlying the edge portion of the occlusive
6046024 Method of producing a fibrin monomer using a biotinylated enzyme and immobilized avidin April 4, 2000
Compositions and methods for avidin immobilized on an inert support material, e.g. agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin
6031149 Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor February 29, 2000
The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous
6030794 Genetically engineered mice and cell lines containing alterations in the genes encoding retinoic February 29, 2000
The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, mice which are heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or
5998155 Stable composition of immobilized protein having affinity for biotin December 7, 1999
Compositions and methods for avidin or protein having affinity for biotin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels for binding biotin and may include a bulking agent, e.g., maltose, and a protectant to maintain the
5986095 Enantioselective preparation of halophenyl alcohols and acylates November 16, 1999
A process is described for preparing a compound of the formula or the S-enantiomer thereof,wherein:R is alkyl, aryl, cycloalkyl, aralkyl, or cycloalkylalkyl,R.sup.1 is halogen;R.sup.2 is halogen, alkyl, cycloalkyl, aryl or ##STR1## wherein the process comprises treating the associated ra
5968024 Ostomy appliance and wound drainage device with self adhering drain system October 19, 1999
An ostomy appliance or wound drainage device having a lower end with an adhesive composition thereon so that when the lower end is folded upon itself, the drainage opening is closed off, or, alternatively, the lower end is made of a material having intrinsic adhesive properties.
5964485 Tube coupling October 12, 1999
A tube coupling is shown, particularly but not exclusively intended for use in joining tubes which have medical and surgical uses. A coupling according to the invention may be used to connect an ostomy bag to a drainage tube, or to connect an incontinence urine collection device to a
5951533 Ostomy appliance and wound drainage device and method of using the same September 14, 1999
An ostomy appliance or wound drainage device having a receptacle side component including a receptacle for receiving and storing waste solids and fluids and a bodyside component for adhering to the patient's skin around the stoma in which the two components are releasably sealed toge
5942406 Gel, slurry or suspension containing immobilized avidin having high biotin binding activity August 24, 1999
Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avi
5912010 Prophylactic and therapeutic treatment of skin sensitization and irritation June 15, 1999
Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one
5859239 Mercaptoalkanoylamino and acylmercaptoalkanoylamino benzoxazepines and benzothiazepines January 12, 1999
Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme and neutral endopeptidase and thus useful as cardiovascular agents.
5859187 Antiviral peptides January 12, 1999
Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulasandthat are useful as antiviral agents.
5856477 Azepinones useful as intermediates in the preparation of inhibitors of angiotensin converting en January 5, 1999
The azepine intermediates of the formula ##STR1## wherein R.sub.6 and R.sub.7 are other than hydrogen are disclosed. These intermediates can be reacted with acylmercaptocarboxylic acids of the formula ##STR2## to give the pharmaceutically active products.
5830496 Wound filler November 3, 1998
A method of treating a wound comprising minimizing pressure on newly formed tissue around the perimeter of the wound by applying within the borders of the wound, a multi-layer laminate having a non-stretchable wound contact layer, a core layer comprising an absorbent material and a stret
5830200 Ostomy coupling November 3, 1998
It would be desirable to have improved designs of ostomy couplings which embody a springy or resilient split ring as a locking ring.In an ostomy coupling, first and second coupling members 50, 60 are held together by a springy flexible split locking ring 70. A plurality of tabs 71 symmet
5827868 Prostaglandin analogs October 27, 1998
Thromboxane receptor antagonist activity is exhibited by compounds of the formula ##STR1## wherein: V is --(CH.sub.2).sub.m --, --O--, or ##STR2## but if V is --O--or ##STR3## R.sup.3 and R.sup.4 must complete an aromatic ring; W is --(CH.sub.2).sub.2 --, --CH.dbd.CH-
5824230 Method and device for separating a component such as fibrin I from blood plasma October 20, 1998
A method and a device for separating a component, such as fibrin monomer from blood, by centrifugation, involve feeding of blood admixed an anticoagulant to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner w
5811292 Lipase esterification processes for resolution of enantiomeric mixtures of intermediates in the September 22, 1998
Methods for the enzymatic resolution of mixtures of enantiomers, such as .beta.-lactam compounds, which may be employed as intermediates in the preparation of taxanes such as taxol, the latter useful in the pharmaceutical field.
5801220 Rapidly disintegrating thickening composition September 1, 1998
A rapid disintegrating and dispersing composition for thickening liquid waste into a thixotropic gel comprises a polymeric acrylic resin and a colloid-forming mixture of microcrystalline cellulose and sodium carboxymethylcellulose. Additional ingredients preferably used in making a t
5789197 Microsomal triglyceride transfer protein August 4, 1998
Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these material
5776933 Method of inhibiting protease July 7, 1998
Novel aminediol compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds in inhibiting retroviral protease, particularly useful in the treatment and/or prevention of HIV infection (AIDS).
5760036 Aminediol protease inhibitors June 2, 1998
Novel aminediol compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds in inhibiting retroviral protease, particularly useful in the treatment and/or prevention of HIV infection (AIDS).
5741428 Rapid centrifugal process for preparing fibrin monomer solution April 21, 1998
In a process of separating a liquid sample having phase portions of different densities by centrifugal separation, a phase separator container is employed. The phase separator container comprises a housing having concentric inner and outer cylindrical walls defining a longitudinal axis
5738784 Device for separating a blood component from blood or plasma April 14, 1998
A method and a device for separating a component, such as fibrin monomer from blood, by centrifugation, involve feeding of blood admixed an anticoagulant to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner w
5723609 Bis (hydroxymethyl) cyclobutyl purines March 3, 1998
Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts wherein R.sub.1 is ##STR2## wherein R.sub.2 is hydrogen, methyl, fluoro, chloro, bromo, iodo, hydroxy or amino; or trifluoromethyl; R.sub.5 is alkyl; R.sub.6 is hydr
5723602 Dual action inhibitors containing a pyridazinodiazepine or pyrazolodiazepine lactam ring March 3, 1998
Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and are thus useful as cardiovascular agents.
5723457 Acylmercaptoalkanoylamino and mercaptoalkanoylamino benzazepines March 3, 1998
Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme and neutral endopeptidase and thus are useful as cardiovascular agents.
5714232 Alginate fabric, its use in wound dressings and surgical haemostats and a process for its manufa February 3, 1998
The invention is a wound dressing prepared from alginate fibers which have good structural integrity, whereby layers are firmly joined together, e.g. by stitching or calendering at a plurality of points to produce a composite fabric.
5709674 Ostomy coupling January 20, 1998
An ostomy coupling includes a first coupling ring attached to a medical grade adhesive pad, a second coupling ring attached to an ostomy pouch, and an intervening ring. The intervening ring is slidable along the lower portion of the cylindrical wall of the first coupling ring. The in

 
 
  Recently Added Patents
High-density 3-dimensional structure
Maltol ether processes and intermediates
Antenna for an automobile
Electrophoresis display having touch screen and method for driving the touch screen
Method and a channel estimating arrangement for performing channel estimation
Analysis, secure access to, and transmission of array images
Toy ball
  Randomly Featured Patents
Method and apparatus for making containers from thermoplastic materials
Air-fuel ratio control system for automotive internal combustion engine or the like with fuel type discrimination capabilities
Sealed light emitting diode assemblies including annular gaskets and methods of making same
Method of etching a dielectric layer to form a contact hole and a via hole and damascene method
Vehicle controller (VCON) for automated durability road (ADR) facility
Door and method of fabricating the same
Circuit for indicating abnormality of three-mode surge absorber of public electric power
Tire tread
Hydro-Elastic engine mount
Proteasome inhibitors and methods of using the same